MD Podcast on the Pharmaceutical Presbyopia Treatments

Richard Lindstrom, MD

Program Director
Founder and Attending Surgeon
Minnesota Eye Consultants
Minneapolis, MN

John P. Berdahl, MD

Vance Thompson Vision 
Associate Professor of Ophthalmology
Sanford School of Medicine
Cataract, Refractive, Glaucoma and Corneal Surgeon
Sioux Falls, South Dakota

Preeya K. Gupta, MD

Founder and Director of Triangle Eye Consultants

Wake Forest and Cary, North Carolina

Edward J. Holland, MD

Professor of Ophthalmology
University of Cincinnati
Director of the Cornea Service
Cincinnati Eye institute
Cincinnati, Ohio

Sheri Rowen, MD

NVISION Eye Centers
Medical and Research Director
Newport Beach, California

Darrell E. White, MD

President and CEO
SkyVision Center
Westlake, Ohio

Elizabeth Yeu, MD

Moderator
Virginia Eye Consultants
Medical Director, CVP Mid-Atlantic
Cornea, Cataract, External Disease and Refractive Surgery
Assistant Professor, Department of Ophthalmology
Eastern Virginia Medical School
Norfolk, Virginia

DISCLOSURE POLICY
It is the policy of Evolve that faculty and other individuals who are in the position to control the content of this activity disclose any real or apparent conflicts of interest relating to the topics of this educational activity. Evolve has full policies in place that will identify and mitigate all conflicts of interest prior to this educational activity.

The following faculty/staff members have the following financial relationships with commercial interests:

Richard Lindstrom, MD, has had a financial agreement or affiliation during the past year with the following commercial interests in the form of Consultant: Acufocus, Aerie Pharmaceuticals, Alcon Vision, Allegro, Bausch Health, Johnson & Johnson Vision, Kala Pharmaceuticals, Imprimis, Surface Ophthamics, Novartis, and Ocular Therapeutix.

John P. Berdahl, MD, has had a financial agreement or affiliation during the past year with the following commercial interests in the form of Consultant: Aerie, Aerpio, Alcon, Allergan, Avedro, Aurea Medical, Bausch + Lomb, Carl Zeiss Meditec, CorneaGen, Dakota Lions Eye Bank, Equinox, Expert Opinion, Glaukos, Gore, Imprimis, iRenix, Iacta Pharmaceuticals, Johnson & Johnson Vision, Kala Pharmaceuticals, Kedalion, MELT Pharmaceuticals, MicroOptx, New World Medical, Ocular Surgical Data, Ocular Therapeutix, Omega Ophthalmic, Orasis, Oyster Point, RxSight, Sight Sciences, Surface Inc., Tarsus, Tear Clear, Vertex Ventures, ViaLase, Vittamed, Vance Thompson Vision, and Visionary Ventures. Speaker’s Bureau: Alcon, Allergan, and Glaukos. Stock/Shareholder: Carl Zeiss Meditec, CorneaGen, Equinox, Expert Opinion, Ocular Surgical Data, Omega Ophthalmic, Surface Inc, and Vance Thompson Vision. 

Preeya K. Gupta, MD, has no financial agreements with commercial interests.

Edward J. Holland, MD, has had a financial agreement or affiliation during the past year with the following commercial interests in the form of Consultant: Abingworth, Aerie Pharmaceuticals, Akros Pharma, Alcon Vision, Aldeyra Therapeutics, Allegro, Allergan, Azura Ophthalmics, BlephEx, BRIM biotech, Carl Zeiss Meditec, Claris Bio, Corneat, CorneaGen, Dompé, Expert Opinion, Eye Point Pharmaceuticals, Glaukos, Hanall, Invirsa, Kala Pharmaceuticals, Mati Therapeutics, Merck, Novartis NIBR, Novartis, Ocular Therapeutix, Ocuphire, Omeros, Oyster Point Pharma, Precise Bio, Prometic Biotherapeutics, ReGentree, Retear, Senju, Shire, Sight Sciences, Slack, Tarsus, TearLab Research, Vomaris, and W.L. Gore and Associates. Grant/Research Support: Alcon Vision, Mati Therapeutics, Novartis, Omeros, Senju, and Shire. Speaker’s Bureau: Alcon Vision, Novartis, Omeros, Senju, and Shire.

Sheri Rowen, MD, has had a financial agreement or affiliation during the past year with the following commercial interests in the form of Consultant and Speaker’s Bureau: Alcon Vision, Allergan, Azura, Bausch + Lomb, and Orasis. Grant/Research Support: Alcon Vision. Share/Stockholder: Orasis.

Darrell E. White, MD, has had a financial agreement or affiliation during the past year with the following commercial interest in the form of Consultant and Stock/Shareholder: Orasis.

Elizabeth Yeu, MD, has had a financial agreement or affiliation during the past year with the following commercial interests in the form of Consultant: Alcon Vision, Allergan, Avedro, Bausch + Lomb, BioTissue, Beaver Visitec, BlephEx, Bruder, Carl Zeiss Meditec, CorneaGen, Dompé, Expert Opinion, EyePoint Pharmaceuticals, Guidepoint, Johnson & Johnson Vision, Kala Pharmaceuticals, Lensar, Merck, Mynosys, Novartis, Ocular Science, Ocular Therapeutix, Ocusoft, Omeros, Oyster Point Pharma, Science Based Health, Shire, Sight Sciences, Sun Pharmaceutical Industries, Surface, Thea, Tarsus, TopCon, TearLab, and Visus Therapeutics. Grant/Research Support: Alcon Vision, BioTissue, Ocular Science, TopCon, and TearLab. Stock/Shareholder: BlephEx, CorneaGen, Melt, Ocular Science, Oyster Point Pharma, and Tarsus.

The staff and planners from Evolve and The Fundingsland Group have no financial relationships with commercial interests.  Nisha Mukherjee, MD, peer reviewer, has no financial relationships with commercial interests.